Ironwood Announces New Drug Application for Duzallo (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2017-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for Duzallo (fixed-dose combination of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news